Calyxo inks $32.7m Series C to remove kidney stones

Questa Capital and CRG led the round.

  • Calyxo’s CVAC Aspiration System helps remove kidney stones
  • Questa Capital invests in expansion-stage healthcare companies
  • CRG has committed more than $3 billion across three funds to date

Calyxo Inc, a medical device company focused on improving care for patients with kidney stones, has raised $32.7 million in Series C financing. Questa Capital and CRG led the round.

“We are proud to invest in Calyxo and its groundbreaking kidney stone treatment technology,” Ryan Drant, founder and managing partner of Questa Capital, said in a statement. “The company’s leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs.”

According to a study published in the Journal of Urology, more than 5 million Americans will pass a kidney stone in 2022, a number that continues with an upward trajectory. Kidney stone disease is a painful condition that brings with it staggering healthcare costs. Current Urology Reports estimates that costs for direct treatment will reach $4.1 billion a year by 2030.

“Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently,” Calyxo said in a statement.